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In recent years, tetanus and measles are esti-  the most disadvantaged children. He found little
mated to account for more than 2.5 million  support for the existence of a replacement
childhood deaths annually; measles alone may  mortality effect.
account for more than 2 million such deaths.
Koenig reviews empirical evidence on the most  Studies on maternal immunization against
effective and feasible strategies for measles  ..id  tetanus showed a great reduction in the number
tetanus vaccination programs.  of neonatal deaths, but considerable uncertainty
about the number of doses needed and how long
Koenig found that tetanus and measles  the immunity lasted. Recent evidence suggests
immunization programs could significantly  that giving the mother two doses of tetanus
reduce deaths among children up to the age of 4  toxoid may confer significant levels of protection
in many developing settings. Vaccinations had a  against neonatal death from tetanus for 15 years
pronounced effect in reducing childhood deaths  or more. Evidence on the impact of a single dose
from measles - with benefits sustained over  is less conclusive.
time, and with the greatest benefits accruing to
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Baltimore,  Maryland,  June  20-22, 1991.In recent years, there has been increased recognition of the
paramount importance of tetanus and measles as causes of
childhood death in the developing world. It has been estimated
that these diseases may together be responsible for more than 2.5
million childhood deaths annually. Considerable debate and
uncertainty remains, however,  concerning the actual reductions
in childhood mortality which would result from the prevention of
these diseases through immunization. Equally important,  many
unresolved questions remain regarding the most cost-effective and
feasible operational strategies for measles and tetanus
vaccination programs. The cbjective of this paper  is to review
existing empirical evidence on tetanus and measles immunization
pertaining to these issues.
MEASLES IMMUNIZATION
Measles has been estimated to account annually for as many as
two million deaths to children worldwide  (WHO, 1985). The risk
period for measles begins when protection conferred by maternal
antibodies wanes, and continues throughout early childhood. The
beginning of the risk period appears to vary considerably between
settings and according to residence, with the onset of measles
cases frequently reported as early as 4-6 months of life in many
urban African settings, but generally later in other settings
such as South Asia (AssaaO, 1983).
Mortality Impact of Immunization
The main studies which have evaluated the impact of meacles
immpnization upon reductions in childhood mortality are
summarized in Table 1. In the following sections, the study
design and analytical approaches taken by each of these studies,
as well as their principal findings, are reviewed.
The Kasongo study in  Zaire represents the earliest attempt
to syste.natically  evaluate the impact of measles vaccination upon
child survival  (The Kasongo Project Team, 1981). All children in
one area born during or after September, 1974  were offered
measles vaccination at 8 months of age. A total of 255 children
in this area accepted measles vaccination during the period of
the study, representing 83 percent of all eligible children.
Three comparison groups of unvaccinated children were also
identified: 1)  children born during the same period from a
neighboring area where vaccination had not been offered, 2)
children from the same area who were born during an earlier
period  (1973- 1974), and 3) children from the neighboring area
also born during this earlier period. Survival status of children
was ascertained through a system of quarterly household morbidity
and mortality surveillance, carried out from mid-1974 through the
end of 1977.
3TABLE  1:  SUMMARY  OF MEASLES  VACCINATION  STUDIES
STUDY  ILOCATION  ISTUDY  PERIOD  STUDY  POPULATIOM  MAIN  FINDINGS
i  - ~  ~  __  _  __  ___  __  ___  __  __  _  [M.IN
THE  KASONGO  ZAIRE  1974-1977  255 VACCINATED  CHILDREN  30-49%
PROJECT  TFAM  3 CONTROL  GROUPS  OF  REDUCTIQN  IN
UNVACCINATED  CHILDREN  7-35 MONTH
l  _______________  _____________  MORTALITY
AABY,  ET AL.  GUINPA-BISSAU  1980-1981  803 VACCINATED  CHILDREN  72% REDUCTION
193 UNVACCINATED  CHILDREN  IN 6-35 MONTH
}  _______________  ______________  _____________  MORTALITY
GARENNE  AND  SENEGAL  LATE  1960s  Krk  31% REDUCTION
CANTRELLE  IN  6 MO.  - 3
YR.  MORTALITY
CLEMENS,  ET AL.  MATLAB,  1982-1984  536 DEATHS  36% REDUCTION
BANGLADESH  1072 AGE-SEX  MATCHED  IN 10-60
CONTROLS  MONTH
__ _ _ _ _ _ _ _ _ _ _ _ _  _____________  __________________________  MORTALITY
KOENIG,  ET AL.  MATLAB,  1982-1985  8135 VACCINATED  CHILDREN  UP TO 46%
BANGLADESH  8135 MATCHED  UNVACCINATED  REDUCTION  IN
CHILDREN  9-60  MONTH
l____________  MORTALITYThe mortality experience of these cohorts of children during
the age interval 7-35 months was compared using life table
techniques. The results of this analysis demonstrated a
peonounced impact of measles vaccination upon childhood mortality
levels  (Figure 1). Mortality among the cohort of vaccinated
children was substantially lower than among the three control
groljps  of unva*ccinated  children: 39 per 1000 vs. 69-95 per 1000
durAng the age period 7-35 months. This translates into
mortality reductions of between 44 to 59 percent among vaccinated
children, depending upon the control group chosen. Differences
between groups were most marked during ages 7-21 months, the
period corresponding to the greatest risk of measles-related
mortality.
Two othec studies from Africa merit consideration. A study
in Guinea-Bissau compared the subsequent one year mortality
experience of two groups of vaccinated children in 1980 and 1981
with two groups of children from the same area and periods who
did not attend a measles campaign  (Aaby,  et al. 1984). Although
the numbers in the study were comparatively small, especially the
number of unvaccinated children (803 vaccinated and 193
unvaccinated children), the results indicated a markedly lower
nortality level during the following year among immunized
cnildren-- as much as 72 percent lower among children aged 6-35
months. In a second study, Garenne and Cantrelle (1986) analyzed
the impact of two measles vaccination campaigns based on data
from the Khombole area of Senegal over the 1965-68 period. The
subsequent mortality experience of vaccinated children aged 6
months to 10 years in a set of villages selected for a measles
vaccination program was compared with a control group of children
from other villages where measles vaccination had not been
offered. The findings of the study indicated a reduction in
mortality among younger vaccinated children (6  months to 3 years)
of 31 percent. The reduction in mortality among older children
(3-10 years) was more modest  (14  percent).
The two other major studies of mortality impact originate
from a measles vaccination program in the Matlab study area of
the International Centre for Diarrhoeal Disease Research
(ICDDR,B) in rural Bangladesh. Since 1966, the ICDDR,B has
maintained a system of continuous demographic surveillance in its
rural field site in Matlab,  consisting of the bi-weekly
registration of vital events and periodic censuses. In 1982, the
study area consisted of 149 villages with a total population of
approximately 180,000. In 1978, half of the study area was
designated as an intervention area for an experimental maternal
and child health/ family planning program provided by the
ICDDR,B; the other half remained a comparison area, with services
limited to the less intensive government program. In early 1982,
as part of a carefully phased expansion of services, measles
vaccination was introduced into two of the four sub-areas of the
intervention area  (termed blocks); this service was expanded to
5FIGURE  1.  COMPARISON OF MORTALITY  EXPERIENCES  OF
VACCINATED AND UNVACCINATED CHILDREN  AGED 7-35  MONTHS:
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SOURCE:  TIlE  KASONGO  PROJECT  TEAM,  1981the remaining two blocks in the fall of 1985. The fact that
measles vaccination was introduced in this phased manner makes it
possible to evaluate its impact upon subsequent mortality.
Thf first evaluation of the impact of the Matlab measles
immunization program was a retrospective case-control study
consisting of 536 deaths to children aged 10-60 months of age
between early 1982 and the end of 1984 (Clemens, et al. 1988).
These cases were randomly matched by age and sex with 1072
controls (i.e., children who survived)from the two blocks where
vaccination was not offered, and compared in terms of their prior
measles immunization status. Measles immunization was found to be
associated with a child mortality rate which was 36 percent lower
during the study period.
The second study based upon the Matlab measles vaccination
program consisted of a longitudinal cohort analysis following
children through late 1985 (Koenig, et al. 1990). All 9-60 month
children in these two blocks who received measles vaccination
during 1982-85 were eligible for inclusion in the study. These
children were randomly matched with unvaccinated children of
similar age from the other half of the intervention area,
resulting in a final analysis cohort of 8135 vaccinated and 8135
unvaccinated children. Through a comparison of the relative
mortality experiences of these two cohorts of children from the
date of vaccination to the end of the observation  (death, out-
migration, exceeding five years of age, or the end of the study
period, October, 1985), it was possible to evaluate the effect of
measles vaccination upon short and longer-term survival. As
Figure 2 shows, a striking differential in cumulative mortality
risks according to vaccination status was evident. At 42 months
from'  the date of vaccination, vaccinated children experienced
mortality risks which were 40 percent lower than their
unvaccinated counterparts.
Replacement Mortality
An issue of direct relevance to the impact of measles
vaccination programs, but one which remains under considerable
debate, is the replacement mortality hypothesis. According to
this hypothesis, children 'saved' from death from a specific
cause may continue to be at elevated risk of death from other
unaddressed causes, resulting in little improvement in overall
survival levels. While potentially relevant to many health
interventions, this hypothesis has most commonly been applied to
the issue of measles and measles immunization  (see  The Kasongo
Project Team, 1981; Mosley, 1985. If substantiated, then the
contribution of measles vaccination may be largely to delay
rather than prevent childhood mortality, calling into question
7FIGURE 2.  CUMULATIVE  MORTALITY RATES BY
MEASLES VACCINATION  STATUS:  MATLAB
INTERVENTION  AREA, 1982-85
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Months  after  vaccinationthe efficacy of this intervention as a means for improving child
survival. The evidence on measles vaccination and replacement
mortality  is considered from two different perslectlves in the
following sections.
Convergence in"Survival Over Time
If replacement mortality was evident, vaccinated children
would be expected to experience improved survival in the short-
run relative to unvaccinated children, but comparatively higher
mortality levels in the longer run, as they would remain highly
vulnerable to death from other causes. The result would be a
convergence between vaccinated and unvaccinaZed children in
survival probabilities over time.
The authors of the Kasongo study presented evidence which
they interpreted as providing support for this hypothesis. Their
analysis indicated that while vaccinated children had improved
survival chances during the ages 7-21 months, the primary risk
period for measles and measles-related mortality, the survival
advantage of vaccinated children tended to diminish at later ages
(22-35 months). However, as Aaby, et al. (1981)  showed in a re-
analysis of the Kasongo data,  too few deaths occurred in this
study population  in this older age group to support the authors'
original conclusions. Instead, the most salient finding of the
study remains the marked reduction in mortality among vaccinated
children throughout the entire age span, w  ch reductions ranging
from 44 to 59 percent lower among children aged 7-35 months.
The study by Clemens, et al. (1988) in Matlab also
considered the issue of replacement mortality in detail. First,
the authors examined whether the protective  efficacy of measles
vaccination for cases and controls selected during the second
half of the year-- cotresponding to after the measles season in
Bangladesh-- might be negative, in contrast to cases and controls
selected during or shortly after the primary measles season, when
protective efficacy should be positive. The finding of a negative
prctective efficacy dujring  the period after the measles season
would re¢lect higher replacement mortality among vaccinated
children. The results, however, did not provide support for a
replacement mortality effect, since the protective efficacy of
vaccination was positive and significant during both periods.
Second, the authors evaluated whether amon, cases and controls
selected in 1982, there was evidence of a reduction in mortality
among vaccinated children in the initial year, followed by higher
mortality rates relative to unvaccinated children in thj ensuing
two years  (1983-84). The results provided no evidence oL  a
decline in the effect of measles vaccination with increasing time
from vaccination, once again failing to provide evidence of a
replacement mortality effect.
9Data from the Matlab cohort study by Koenia, et al. (1990)
lead to similar conclusions. Among the cohort of children
vaccinated at c12 months of age and their matched controls, if
replacement mortality were present, one would expect to  see
higher mortality among vaccinated children with increasing time
from vaccination, leading to a partial or complete convergence in
survival curves for the two groups. The results instead indicate
that vaccinated children continue to experience relatively lower
mortality at almost all subsequent age intervals.  Moreover, the
magnitude of reductioi.s  in mortality from measles vaccination
reported in thes  two studies (between 36 and 46 percent) suggest
that even if such an effect were present, its impact upon
lessening the mortality gains resulting from measles v,=cination
would be quite minor. The studies from Matlab thus provide no
support for the existence of a replacement mortality effect.
Impact Among High-Risk Children
If replacement mortality were present, it should also be
expected that the most vulnerable children would benefit least
from measles immunization, since it is these children who
continue to remain most at risk of death from other unaddressed
causes. Within the context of South Asia, high risk children
would include females and those from the poorest households, both
of  which have been shown to experience significantly higher
mortality risks during the early childhood period  (D'Souza and
Chen, 1980; D'Souza and Bhuiva, 1982). Data from the  Matlab
cohort study on measles immunization permit a more detailed
investigation of this hypothesis.
Figure 3 shows life table results of the aifferential impact
of measles vaccination upon mortality according to sex of child.
If replacement mortality was present, little difference in the
survival curves of female children according to vaccination
status would be expected, since thev would continue to be at high
risk of death from other causes.  The results of this figure do
not provide support for the replacement mortality hypothesis, and
in fact, indicate the opposite-- that female children may benefit
more from vaccination in terms of mortality reductions.
Vaccinating a  female child against measles provides her with
roughly the same survival chances as an unvaccinated male child.
These result, are illustrated in greater detail in Figure 4.
Although the relative reductions in mortality are not
significantly different for male and female children (36 percent
and 41 percent, respectively),  because of the much higher
mortality levels among female children during this age period,
the absolute reduction in mortality for female children is more
than twice that for male children (37  deaths vs. 17 deaths per,
1000 live births at 42 months post-vaccination).
10FIGURE  3.  CUMULATIVE MORTALITY RATES  BY
MEASLES  VACCINATION STATUS AND  BY  SEX:
MATLAB INTERVENTION  AREA,  1982-85
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CUMULATIVE  MORTALITY  RATE  42  MONTHS  AFTER  VACCINATIONSimilar results are evident in the relationship between
measles vaccination, household area, and child mortality, a
primary indicator of socioeconomic status among rural Bangladeshi
families (Figure 5). While the presence of a child replacement
effect would argue in favor of a much weaker effect of
vaccination upbn child survival among children from the poorest
households  (area of <200 sq ft), no such association is evident.
The results indicate that children of all socioeconomic strata
benefit from measles vaccination in terms of lower mortality
risks. Although not as pronounced as in the case of sex, children
in the poorest households benefit somewhat more from vaccination
in terms of absolute reductions in mortality.
In conclusion, the evidence considered provides no direct or
indirect support for the existence of a child replacement effect,
which would diminish the contribution of measles vaccination to
improved child survival. The available evidence instead indicates
that the effect of measles vaccination is sustained over time,
and that ti  a greatest benefits from vaccination appear to be
found among the most vulnerable children. As such, measles
vaccination may reduce not only overall mortality levels but also
inequalities between groups in their survival chances.
Potential Selection Bias
A primary issue of concern in all assessments of  measles
vaccination  impact is that vaccinated children represent a
spegial group of children who may have better health and survival
prospects, even in the absence of measles vaccination. If this
were the case, then the lower mortality risks observed may be due
in large part to the special nature of vaccinated children,
rather than to measles vaccination per se. The studies of measles
vaccination  impact have adopted a number of different approaches
to dealing with the issue of potential selection bias.
The issue of pctential selection bias was not directly
addressed in the  ;asongo  study in Zaire. However, the authors
presented survival data from the area where measles vaccination
had been offered for both the 255 eligible children who were
vaccinated as well as the 51 eligible children who were not; many
of these latter children may have been self-selected for poorer
survival outcomes. Analysis of the survival probabilities of all
306 children together takes into account any possible selection
bias between vaccinated and unvaccinated children. The 7-35 month
mortality rate for this group was 48.3 per 1000, an increase
from the rate of 39.1 per 1000 for vaccinated children alone.
However, this still translates into a reduction in mortality
relative to the other three control groups of between 30 to 49
percent, indicating a sizeable impact of vaccination upon
13FIGURE  5.  CUMULATIVE  MORTALITY  RATES BY  MEASLES  VACCINATION
STATUS AND  BY HOUSEHOLD  AREA:  MATLAB
INTERVENTION  AREA,  1982-85
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CUMULATIVE  MORTALITY  RATE  42  MONTHS  AFTER  VACCINATIONmortality even when possible selection bias is taken into
account.
In both of the other African studies by Aaby, et al. (1984)
and Garenne and Caitrelle (1986), control groups consisted  of
unvaccinated children from the same areas where measles
vaccination was offered. As such, selection bias may represent an
important confounding factor, with controls disproportionately
comprised of children who face independently higher mortality
risks. This may account in part for the extremely large
reductions in mortality reported by the Aaby, et al. in the
Guinea-Bissau study.
In the case-control study by Clemens, et al. (1988) in
Matlab,  little or no effect of measles vaccination upon
mortality would have been expected during the first year of the
study, since the program was introduced at the end  of the annual
measles season, unless vaccination acceptors constituted a
special group with lower overall mortality risks,  The finding
that there was no protective effect from measles vaccination
during the first year of the study provides strong evidence that
measles vaccinees did not constitute a select group with better
survival chances from the onset (WHO, 1987). In addition, the
reported finding by the authors of a 36 percent mortality risk
among vaccinated children was based upon multivariate analysis
which controlled for the effects of a number of potentially
confounding demographic and socioeconomic characteristics which.
might differentiate vaccinated from unvaccinated children.
The Matlab cohort study by Koenig, et al. (1990) also
considered the issue of potential selection bias from several
different perspectives. First, the study examined whether the
families of vaccinated and unvaccinated children differed on
other indicators of health behavior which might account for lower
mortality among the former group of children. No difference
between groups was evident with respect to one important
indicator of health behavior--  use of contraception. Second, the
authors carried out multivariate analysis to control for the
effects of a number of potentially confounding variables  (birth
order, sex, maternal education, and area of household) on which
vaccinated and unvaccinated children might differ. The results
indicated that even after controlling for these factors,
vaccinated children still experienced mortality levels which were
46 percent lower. Lastly, the authors examined whether vaccinated
children from the two blocks where measles vaccine was offered
may have been self-selected for better survival-- i.e., that a
primary reason why children remained unvaccinated in these blocks
was that they failed to live long enough to be vaccinated.  To
take this into account, they constructed a second data set which
included all children-- both vaccinated as well as unvaccinated--
from the two blocks where measles vaccination had been offered,
and randomly rematched  with the pool of unvaccinated children
15from the other two blocks. These procedures resulted in 9871
children from each of the two areas. When re-analyzed, the
results indicated a slightly reduced but still substantial effect
of measles vaccination, with children from the area with measles
vaccination still experiencing mortality risks which were 40
percent lower than unvaccinated controls. The authors viewed this
figure as a mi~himum  estimate of the effect of measles vaccination
upon child mortality  in this population.
Age at Immunization
A corollary issue of interest concerns the optimal upper and
lower age boundaries for measles vaccination. Current WHO
guidelines recommend 9 months of age as the optimal age for
measles vaccination  (WHO, 1982). The focus within immunization
programs has generally been on reaching all children from 9
months to 2 years of age. One of the few studies to address this
issue has been the study in Bangladesh by Koenig, et al. (1990).
The results of life table analysis are summarized in Figure 6.
Although the largest absolute reductions in mortality occurred
among children who were vaccinated at <12 months of life,
substantial and statistically significant reductions were also
observed among children vaccinated during the 2nd and 3rd years
of life. Although a reduction in mortality was also observed for
children vaccinated at above three years, this was not
statistically significant, owing to the low mortality rate and
small numbers of deaths at these older ages. These findings
indicate that extending the priority target group for measles
vaccination to all children under 3 years of age is likely to
bring about significant further reductions in mortality in
setiings such as rural Bangladesh.
It.  has been recognized that in many settings, significant
proportions of young children contract measles before nine months
of age, frequently with resultant high case-fatality rates. This
has spawned efforts toward the development of a new generation of
measles vaccines which can be administered at earlier ages, 4-6
months of age (Markowitz, 1990). The incremental gains in
mortality reduction from the introduction of these new vaccines
will be contingent upon the following conditions:
1) The prevalence of measles infections among children <9 months
of age
2) The level of protective efficacy provided by these new
vaccines
3) The extent to which existing measles vaccination programs  (9+
months) may have already reduced such ear.ly  measles cases through
the elimination of the transmission mechanism through older
children/ siblings
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CUMULATIVE  MORTALITY  RATE 36  MONTHS  AFTER  VACCINATION
*Reflects  rates  to  24  montlhs  after  vaccination
SOTJRCF:  KOENIG,  ET  AL.  1990TETANUS IMMUNIZATION
Tetanus has been estimated to be responsible for at least
500,000 neonatal deaths annually (Stanfield and Galazka, 1984).
Deaths due to neonatal tetanus result largely from the infection
of the umbilical stump by Clostridium tetani. Tetanus deaths are
extremely rare,during the initial days of life, rise rapidly to a
peak during the 7th to 8th dav of life, then decline through the
rest of the neonatal period. Neonatal tetanus is effectively
prevented through the maintainence of hygienic conditions at the
time of delivery, and/or through passive immunity through the
immunization of the mother prior to or during pregnancy.
Tetanus immunization differs from immunization against
other childhood diseases such as measles in an important way.
Because protection is provided passively through immunization of
the mother, the risks of neonatal tetanus and tetanus mortality
persist undiminished throughout the mother's reproductive period.
This contrasts with immunization against other childhood
infectious diseases such as measles, with well-defined risk
periods during which the risk of death generally steadily
diminishes over time.  Thus, in addition to the magnitude of
neonatal mortality reductions resulting from maternal tetanus
immunization, the issues of duration of immunity and the number
of doses required to ach'eve this immunity become of paramount
importance for immunization strategies. In the following
sections, empirical evidence bearing on these issues is reviewed.
An extensive literature has accumulated on the effect of
tetanus toxoid immunization upon protective antibody levels (see
Jones, 1983). However, the number of studies assessing the impact
of  maternal tetanus immunization upon neonatal mortality levels
is much smaller (Table 2).
Reductions in Neonatal Deaths Due to Tetanus
One of the earliest studies from a developing country on the
mortality impact of maternal tetanus immunization was a study
by Schofield, et al. (1961) in New Guinea carried out during
1959-60. All women in an area where a system of health clinics
had been established were offered tetanus toxoid during
pregnancy. The size of the study population was relatively small:
234 births and 175 births to mothers who received 2 and 3
injections, respectively, and a control group of 160 births to
mothers who received either 0 or 1 injections.  Comparison of
these three groups showed that two or more tetanus immunizations
resulted in a significant reduction in mortality from neonatal
tetanus; from 100 per 1000 live births in the control group to 34
per 1000 among births to women receiving two injections. Among
births to women receiving three injections, only 1 neonatal
18TABLE  2:  SUMMARY  OF MATERNAL  TETANUS  IMMUNIZATION  STUDIES
STUDY  DURATION  OF
STUDY  LOCATION  PERIOD  STUDY  POPULATION  MORTALITY  IMPACT  PROTECTION
SCHOFIELD,  NEW GUINEAU  1959-1960  0 TT:  86 BIRTHS  REDUCTION  IN NEONATAL  <  12 MONTHS
ET AL.  1 TT:  74 BIRTHS  TETANUS  DEATHS  FROM
2 TT:  234 BIRTHS  100 PER  1000 TO 34 PER
3 TT:  175 BIRTHS  1000 WITH  2 TT DOSES
AND TO  6 PER 1000 WITH
3 TT  DOSES
NEWELL,  COLOMBIA  1961-1966  0 TT:  270 AND  REDUCTION  IN NEONATAL  UP TO 4 YEARS
ET AL.  347 BIRTHS  TETANUS  DEATHS  FROM 78
1 TT:  224 BIRTHS  TO 0 PER 1000 TO WOMEN
2-3 TT:  341 BIRTHS  WITH  2-3 TT DOSES
BLACK,  MATLAB,  1974-1977  0 TT:  4386 BIRTHS  33% REDUCTION  IN  1 TT:  UP  TO 20 MOS.
ET AL.  BANGLADESH  1 TT:  1265 BIRTHS  NEONATAL  MORTALITY  2 TT: UP TO  32 MOS.
2 TT:  2990 BIRTHS  WITH  2 TT DOSES  DURING
1975-77  PERIOD
RAHMAN,  MATLAB,  1974-1979  0 TT: 7237 BIRTHS  REDUCTIONS  IN NEONATAL  1 TT:  NS
ET  AL.  BANGLADESH  1 TT:  486 BIRTHS  MORTALITY  OF 18% AND  2 TT: UP TO 5 YEARS
2 TT:  956 AND  49% WiTH  2 TT DOSES,
934  BIRTHS  DEPENDING  ON  DURATION
KOENIG,  MATLAB,  1973-1989  0 TT:  10745 BIRTHS  37% REDUCTION  IN  1 TT: UP TO 4 YEARS
ET AL.  BANGLADESH  1 TT:  2718 BIRTHS  NEONATAL  MORTALITY  2 TT: UP TO  15 YRS.
2 TT  7891 BIRTHS  WITH  2 TT DOSES  DURING
1975-79  PERIOD  i}tetanus case out of 175 births was reported, a rate of 6 per 1000
live births.
Further conclusive evidence on the efficacy of tetanus
immunization in reducing neonatal tetanus deaths is found in the
study by Newell, et al. (1966) in Colombia during the 1961-1966
period. This study consisted of a double-blind experiment in
which all registered women were randomly assigned to one of two
groups and offered either tetanus toxoid or influenza-virus
vaccine. Subsequent births to these women during 1961-66, as well
as deaths to these births and specific cause of death, were then
followed. The results demonstrated no  neonatal tetanus deaths
during this period among births to women who had received 2-3
tetanus immunizations, compared to a rate of 78 ner 1000 live
births among the control group whose mothers r  - ;ved  2-3
injections of the influenza vaccine.
The Matlab study area is the source of  much of the
conclusive evidence on the effectiveness of maternal tetanus
immunization in reducing mortality from neonatal tetanus. As part
of a large-scale cholera vaccine trial in the Matlab study area
in 1974, non-pregnant adult women and <5 year children received
tetanus toxoid as a placebo. A total of 93,000 individuals
participated in this trial, which was randomized on an individual
basis, with participants receiving either 1 or 2
injections of cholera toxoid or 1 or 2 doses of tetanus toxoid,
all on a double-blind basis. Black et al. (1980)  analyzed the
mortality impact of tetanus toxoi6 placebo in this trial upon two
cohorts of children born during 1975-77 to mothers who
participated in the 1974 vaccine trial. A recent study by Koenig,
et al. (1991b) extended the original study through the 1975-89
period in the comparison area only, which has remained a
population largely unimmunized against tetanus until recently.,
Finally, Rahman, et al. (1982)  analyzed the mortality experience
of children born during 1978-79 in the Matlab study area. Two
groups of births to mothers immunized against tetanus were
evaluated: those  who had received tetanus toxoid while not
pregnant as part of the 1974 vaccine trial described above, and
those who received tetanus toxoid while pregnant in 1978-79, as
part of the expanded MCH-family planning program introduced in
half of the Matlab study area.
In the absence of conclusive diagnosis of  neonatal tetanus
deaths, the Bangladesh studies  used mortality during days 4-14
of life as a  proxy for neonatal tetanus deaths. For the two birth
cohorts combined, the study by Black, et al. showed that two
injections of tetanus toxoid resulted in a reduction in  4-14 day
mortality by 68 percent relative to the control group who
received cholera vaccine (from 25 to 8 per 1000), a highly
significant effect. The study by Rahnan, et al. found that
relative to births to unimmunized mothers, two tetanus toxoid
injections during pregnancy resulted in statistically significant
20reduction in 4-14 day mortality of 69 percent; the effect of
having received two tetanus toxoid injections through the vaccine
trial an average of 4 1/2 years earlier also resulted in a
substantially lower 4-14 day mortality rate (by 41 percent),
although this difference was statistically significant in only
one of the two areas.
Reductions in Neonatal Mortality
The considerable geographical variability in the importance
of neonatal tetanus as a cause of death has long been recognized
(Bytchenko, 1966).  Data from retrospective surveys in a number
of Asian and African countries indicated neonatal tetanus death
rates ranging from 3 to 31 per 1000 live births, with tetanus
accounting for from 8 to 60 percent of all neonatal deaths
(Foster, 1984). In addition to true variability across settings
in the importance of neonatal tetanus as a cause of death, these
figures are also likely to reflect differences in both under- as
well as over-reporting of tetanus as a cause of neonatal death.
The Matlab study area in rural Bangladesh has provided much
of the reliable evidence on the actual or potential  reductions
in mortality resulting from tetanus immunization (Table 3). The
study by Black, et al. showed that two injections of tetanus
toxoid reduced neonatal mortality in subsequent births by 33
percent. Similar results are obtained from the data presented by
Koenig, et al. in the -xtension of this study. Over the five year
period following the vaccine trial (1975-79), two doses of
tetanus toxoid were associated with a 37 percent reduction in
neornatal  mortality. The findings of  Rahman, et al. were
more variable, with reductions in neonatal mortality ranging as
low as 18 percent among births to mothers who received two
injections of tetanus toxoid an average of almost five years
early as part of the cholera vaccine trial, to as high as 49
percent among births whose mothers had recently been immunized
while pregnant with two tetanus toxoid injections, as part of the
MCH-family planning intervention program.
Given the very high efficacy of two doses of tetanus toxoid
in eliminating tetanus in at least the short-term, accurate data
on diagnosed cause of neonatal death among unimmunized
populations should also provide a reasonably precise picture of
the potential reductions in neonatal mortality resulting from
tetanus immunization programs. Table 3 also shows data from other
studies in Bangladesh on the prevalence of neonatal tetanus
death. Data presented by Koenig, et al. (1991a) on causes of
death in the Matlab comparison area, when adjusted for the
confounding effects of tetanus immunization delivered through the
1974 cholera vaccine trial described earlier, indicated that
tetanus accounted for 27 percent of neonatal deaths in this area
21TABLE  3:  SUMMARY  OF FINDINGS  FROM  BANGLADESH  IMMUNIZATION  AND  CAUSE  OF DEATH  STUDIES
ON NEONATAL  TETANUS
NEONATAL  MORTALITY  RATE  (PER 1000)
____________-_____________________-  % REDUCTION  IN
IMMUNIZATION  STUDIES  0 TT  2 TT  NEONATAL  MORTALITY
BLACK,  ET AL.  (1980):
1975-77  BIRTHS  59.7  39.8  33.3%
RAHMAN,  ET AL.  (1982):
IMMUNIZED  IN 1974  78.3  63.8  18.5%
IMMUNIZED  IN 1978-79  78.3  42.8  48.8%
KOENIG,  ET AL.  (1991b):
1975-79  BIRTHS  78.2  49.5  36.7%
NEONATAL  TETANUS  MORTALITY  RATE  % OF ALL
CAUSE  OF DEATH  STUDIES  (PER 1000)  NEONATAL  DEATHS
BHATIA  (1989):
1982-83  MATLAB
COMPARISON  AREA  13.7  20.4%
KOENIG,  ET AL.  (1991a):
l  1986-87  MATLAB
COMPARISON  AREA  18.6*  27.2%*
HLADY,  ET AL.  (1991):
N. BANGLADESH  DIVISION  18.2  33.9%
*Adjusted  for the  effects  of the  1974 vaccine  trial.during the 1986-87 period. An eailier study by Bhatia  (1989)  of
1982-83 infant deaths in the Matlab study area found that tetanus
accounted for 20 percent of all neonatal deaths in the comparison
area. However, the Bhatia study did not adjust the effects of the
1974 vaccine trial, so that tetanus deaths are likely to have
been underestimated  in this study.
It should also be emphasized that the earlier findings from
Matlab, indicating reductions in neonatal mortality by one-third
or mora  (Black, et al. 1980; Koenig, et al. 1991a) may not be
inconsistent with the cause of death estimates of neonatal
tetanus cited above. There is evidence of a steady decline in 4-
14 day mortality in the Matlab study area since the late 1970s
among births to  unimmunized mothers (Koenig, et al. 1991b),
although the factors which have contributed to this decline
remain poorly understood. At the same time, a recent study in a
separate area of rural Bangladesh, based upon one year
retrospective survey data, reported somewhat higher levels of
tetanus-related mortality  (34 percent of reported neonatal
deaths), raising questions about whether neonatal tetanus levels
may be somewhat lower in the Matlab area than for Bangladesh as a
whole  (Hlady, et al. 1991).
Duration of Immunity
In the Colombian study, no neonatal tetanus deaths were
reported among mothers who were immunized during pregnancy with 2
or 3 injections of tetanus toxoid and gave birth over the 1961-66
period  (tNewell,  et al. 1966). This result provided evidence that
the protection conferred by maternal tetanAus  immunization
appeared to last for a period of at least four years. Black, et
al. (1980) in their Matlab study found that two injections of
tetanus toxoid resulted in significantly lower 4-14 day mortality
levels through 21-32 months after immunization. The study by
Rahman, et al.  (1982) in Matlab also provided evidence of
extended durations of protection through maternal tetanus
immunization. Their findings showed that 1978-79 births to
mothers immunized with two injections of  tetanus toxoid during
the 1974 cholera vaccine trial continued to experience
significantly lower 4-14 day mortality rates than among the non-
immunized group,  indicating that two iniections of tetanus toxoid
may confer significant levels of protection against tetanus for a
duration of as long as five years.
These upper bounds on the duration of immunity reported in
all of forementioned studies have been defined by the end of the
respective study periods, rather than by a quantifiable
dimunition in protective immunity. The recent study by Koenig, et
al. (1991b), which examined the duration of immunity conferred by
tetanus immunization in the 1974 cholera vaccine trial over the
231975-89 period, provides the most conclusive evidence to date on
loiR,-term  protection conferred by maternal tetanus immunization.
Figure 7 shows three-year moving averages in 4-14 day mortality
according to 1974 vaccination status for births to mothers
residing in the Matlab comparison area. While mortality rates
were comparable in the period prior to the vaccine trial (1973-
74), a sharp differential in mortality by vaccination status is
observed subsequent to the 1974 trial. Although)  some narrowing in
mortality rates between groups is evident over time, the
mortality rates for the diffeerent  groups did not converge over
time. Separate analysis by the authors indicated that relative to
the unimmunized group, the reduction in 4-14 day mortality among
the group receiving two injections of tetanus toxoid was highly
statistically significant  (p  <.01) for 8 years and remained
significant  (p <.05) through 1989 (with the exception of 1985-
86), a period of 15 years. Thus, even in 1989, the 4-14 day
mortality rate for the two injection group was 6 per 1000,
compared to 23 per 1000 in the unimmunized group.
Number of Doses
One Dose
Con iderable interest has centered upon the degree of
protect.,n provided by one dose of tetanus toxoid, since an
effective single dose would greatly simplify the delivery of
maternal tetanus immunization. The findings on this issue with
respect to mortality impact have been at best inconsistent, and
not infrequently contradictory. For example, the New Guinea study
found no differences in the neonatal tetanus rates between the
small numbers of births to mothers with one injection vs. no
injections, with both groups experiencing markedly higher
neonatal tetanus rates than those who received 2 or 3 tetanus
injections. The Colombian study, on the other hand, reported
somewhat lower neonatal tetanus rates among births who received 1
vs. 0 tetanus toxoid injections, although this difference was not
statistically significant and the rate for the 1 dose group was
still considerably higher than the group who received 2-3
injections (40 vs. 0 per 1000). The small numbers of cases
included in both of these studies, however, make definitive
conclusions difficult.
Once again, the most persuasive evidence on the issue of a
single tetanus toxoid dose comes from the Matlab study area.
However, even within the Matlab study area, the findings on this
issue have not been entirely consistent. The effect of one dose
is closely linked to the issue of duration of protective
immunity. As shown in Figure 8, the study by Black, et al. found
that one injection of tetanus toxoid was associated with
significantly lower 4-14 day mortality 9-20 months after
24FIGURE 7.  DURATION OF PROTECTIVE IMMUNITY  PROVIDED BY
MATERNAL TETANUS TOXOID IMMUNIZATION AGAINST 4-14
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injection group. However, for the period 21-32 months post-
immunization, the rate for this group was no longer significantly
lower, but in fact substantially higher than fUr the two
injection group,  leading the authors to conclude that a single
dose did not proviue meaningful protection for longer than 20
months. The findings of the Matlab study by Rahman, et al. led
them to conclude one injection of tetanus toxoid did not confer a
meaningful  level of protection. However, as Figure 8 shows, the
results of their study  indicated that among the small number of
births to women who received only one injection of tetanus toxoid
in the 1974 vaccine trial (N= 362), 4-14 day mortality rates were
substantially lower than for the unimmunized group and only
slightly higher than for the two dose group (34, 25, and 20 per
1000). However, 4-14 day mortality rates among the group who
received only a single injection while pregnant through the 1978-
79 immunization program were markedly higher than either of the
two immunization groups, and twice as high as for the  single
injection group in the 1974 vaccine trial. This discrepant
finding may be explained by the small numbers of births belonging
to this group  (N=124), as well as the highly selective nature of
those who dropped out of the program after receiving only one
injection (see subsequent discussion).
The recent study Matlab study by Koenig and colleagues
(1991b) provides additional and contrasting evidence on the
effect of a single tetanus toxoid dose. As Figure 7 shows, 4-14
day mortality for the one tetanus toxoid injection group closely
parallels that for the two injection group not just in the short-
run, but for the entire period of observation.  The authors'
analysis showed that relative to the group of births to
unimmunized mothers, lower 4-14 day mortality among the one
injection group was statistically significant through 1978-79;
for a period of up to four years. At the same time, while not
attaining statistical significance, mortality for the one
injection group remained below one-half that for the unimmunized
group in almost all subsequent years. For the 1975-89 period as a
whole, 4-14 day mortality for the one injection group was 12.5
per 1000 live births, significantly lower than for the
unimmunized group  (28.4 per 1000) and even slightly below that
for the two injection group (13.8 per 1000).
3+ Doses
Empirical evidence on the incremental mortality gains from
more than two doses of tetanus toxoid is also slender and
generally based upon very small study populations. The study in
New Guinea found that three injections of tetanus toxoid during
pregnancy conferred a higher level of protection against neonatal
tetanus compared to two doses, with a reduction in neonlatal
tetanus mortality from 34.2 deaths per 1000 to 5.7 per 1000
27(Schofield, et al. 1961). In contrast, the Colombian study found
no difference in neonatal tetanus mortality rates between births
whose mothers received 2 versus 3 tetanus injections; both groups
experienced no recorded tetanus cases or deaths during the study
period of more than fcir years (Newell, et al. 1966). Finally,
data in the Matlab study by Rahman, et al. (1982)  allow the
comparison of the following 4-14 day mortality rates:
Tetanus  4-14 Day Mortality
Immunization Status  Rate  (per 1000)  (N)
2 doses (1978-79)  10.7  (934)
2 doses  (1978-79), 1 dose  (1974)  15.6  (64)
2 doses  (1978-79), 2 doses  (1974)  7.0  (142)
Although the number of cases is small, the results provide no
evidence of a consistent further reduction in 4-14 day mortality
rates with either 3 or 4 doses of tetanus toxoid, relative to the
group who received only two injections while pregnant in 1978-79,
during the interval of the study period.
Further corroboration of the Matlab findings through
serological studies would be desirable, particularly with respect
to the effects of a single dose of tetanus toxoid, given the
uncertainties which persist. One limitation common to all of
these studies has been the use of 4-14 day mortality as an
indicator of tetanus mortality. While most neonatal tetanus
deaths are known to be clustered in this period, recent work in
Matlab has shown that tetanus may account for only roughly half
of all deaths during this age period  (Koenig, et al. 1991a),
leading to considerable imprecision in this measure as an
indicator of tetanus-related mortality. It should also be
recognized thesu studies demonstrate significant reductions in,
but not necessarily the elimination of, neonatal deaths due to
tetanus-- the stated objective of the Expanded Program on
Immunization, and one which might lead to quite different
immunization strategies.  The recent findings from Matlab
nevertheless provide strong evidence that current maternal
tetanus immunization strategies  may confer significant levels of
protection for a much more extended period than has previously
been believed. A single injection of  tetanus toxoid may also
confer a significant degree of protection against tetanus for at
least several years, while two injections may provide significant
protection throughout much of a woman's reproductive period.
28Potential Selection Bias
The  issue  of  potential  selection  bias  among  births  to
vaccinated and unvaccinated mothers has been less of a concern in
the studies on the impact of tetanus immunization. One reason is
that several of the major studies have been based upon controlled
field experiments whose design effectively eliminated the
possibility of such selection bias.  The field trial by Newell,
et al. in Colombia  (1966), and the 1974 cholera vaccine trial in
Matlab, on which the studies by Black, et al. (1980)  and Koenig,
et al. (1991b) were based, were both double-blind, controlled
field trials. A second reason why selection bias may be of less
concern with regard to neonatal immunization studies has been the
absence of evidence suggesting that unimmunized mothers differ
from immunized mothers in behavior (other  than immunization)
which predisposes the children of the former to higher risks of
neonatal tetanus. A third and related factor has been the absence
of evidence suggesting that children at risk of death from
tetanus represent an especially vulnerable group who are also at
much higher risk of death from other neonatal causes.
Nevertheless, in the studies considered which were not based
upon controlled experiments, the possibility of potential
selection bias cannot be ruled out. For example, in the study in
Jew  Guinea, a primary reason for non-immunization (86 cases) was
that mothers came too late in pregnancy to be immunized. The
possibility that such women constitute a highly selective group
whose children are predisposed toward higher risks of tetanus
cannot be ruled out, although the authors view this as unlikely.
Selection bias may have played a more important role in some
of tthe  Matlab findings reported by Rahman, et al. (1982).
Although maternal tetanus coverage rates subsequently reached
very high levels (when offered to all reproductive-aged women),
at the time of this study, when mada available only during
pregnancy, or.ly  one-third of eligible women had accepted
immunization. It could plausibly be argued that these women may
represent a highly selective group who would face lower mortality
risks-- and unimmunized women conversely higher mortality risks--
even in the absence of this program. (The dependent variable of
4-14 day mortality leaves open the possibility for selection bias
with respect to both tetanus as well non-tetanus deaths, since
this measure reflects both). This would help to explain the much
larger reduction in neonatal mortality  rates among births to
mothers who received two injections during the 1978-79 program
compared to the other studies from Matlab  (49  percent lower).
This might also partially account for the absence of a
significant effect among the small one dose group, which may
consist of a higher proportion of high risk mothers.
29Mortality at Later Ages
An additional argument advanced for tetanus immunization is
the protection it provides against tetanus beyond the neonatal
period.  The available empirical evidence on this issue, however,
suggests that the magnitude of this additional mortality effect
may be  quite modest. For example, a study of causes of childhood
death in the Matlab comparison area during 1986-87-- where
tetanus immunization coverage levels were extremely low--
indicated that tetanus accounted for only 3 percent of post-
neonatal and <1 percent of 1-4 year deaths  (Koenig, et al.
1991a). Similarly, a population-based study of 1037 deaths to
adult women in the Matlab study area during 1976-85 found that
only 6 were attributable to tetanus, representing less than 1
percent of all such deaths  (Fauveau, et al. 1987). These findings
indicate that from the standpoint of mortality impact, the
benefits from tetanus immunization will derive largely from a
reduction in neonatal tetanus mortality.
ESTIMATES  OF  POTENTIAL  MORTALITY REDUCTIONS FROM MEASLES AND
TETANUS IMMUNIZATION
The recent study by Koenig, et al. (1991a)  allows the
estimation of the mortality impact of measles and tetanus
immunization for  rural Bangladeshi children. In this study, the
survival status of a cohort of 8161 births, representing all
births within the Matlab comparison area during 1982-83, was
followed through the end of 1987 to estimate <5 year mortality
levels in a largely unimmunized population. The authors then
applied the previously reported findings from Matlab on cause of
death and vaccination  impact, in addition to data on the age
distribution of mortality, applying the most liberal estimate of
mortality reduction for each case, to estimate reductions in
mortality based upon the elimination of deaths from these causes.
The results of this exercise for measles and tetanus mortality
are shown in Figure 9.
For this population of children, the elimination of tetanus
and measles through immunization could be expected to reduce
infant mortality  levels from the previous level of 116 per 1000
live births to 91 per 1000 live births. It is apparent that most
of this reduction would occur through a reduction in neonatal
mortality levels  (from 69 to 50 per 1000 live births) as a result
of tetanus immunization; the reduction in post-neonatal mortality
levels will be quite modest  (from 47 to 41 per 1000 live births).
A marked decline in 1-4 year mortality is also evident as a
result of large effect of measles vaccination, with mortality
between these ages declining from 90 per 1000 to 50 per 1000 live
30births. Overall, the impact of eliminating measles and tetanus
mortality through immunization would be to reduce <5 year
mortality from the baseline level of 206 per 1000 to 140 per 1000
live births, a reduction of 32 percent. Two caveats are in order.
First, as the authors point out, a  number of assumptions have
beer built into these estimates, with the result that the actual
reductions in mortality could be  either over- or underestimated
by these figures.  Second, these estimates are specific to one
area in rural Bangladesh, and the likelihood exists that likely
mortality reductions might vary considerably in other settings,
or even in other parts of Bangladesh.
31FIGURE  9.  ESTIMATED  REDUCTIONS  IN INFANT  AND CHILD
MORTALITY  FROM TETANUS  AND MEASLES  IMMUNIZATION:
1982-83  MATLAB  COMPARISON AREA  BIRTH COHORT
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